IN2012DN03449A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03449A IN2012DN03449A IN3449DEN2012A IN2012DN03449A IN 2012DN03449 A IN2012DN03449 A IN 2012DN03449A IN 3449DEN2012 A IN3449DEN2012 A IN 3449DEN2012A IN 2012DN03449 A IN2012DN03449 A IN 2012DN03449A
- Authority
- IN
- India
- Prior art keywords
- heteroary
- alkyl
- formula
- disclosed
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are CCRI receptor antagonists of the formula (1),wherein X is nitorgen or, C-R.; Ar1 is carbocyele, heteroary or heterocyclyl each optionally substituted by one to three Ra; Ar2 is earboeyele, heteroary or heterocyely, each optionally substituted by one to two R1 is hydrogen, C16 alkyl or C1-6 alkoxyC 1-6 alkyl, Also disclosed are compositions, methods of making and using compounds of the formula (1).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25359009P | 2009-10-21 | 2009-10-21 | |
PCT/US2010/053142 WO2011049917A1 (en) | 2009-10-21 | 2010-10-19 | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03449A true IN2012DN03449A (en) | 2015-10-23 |
Family
ID=43126891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3449DEN2012 IN2012DN03449A (en) | 2009-10-21 | 2010-10-19 |
Country Status (29)
Country | Link |
---|---|
US (1) | US9056858B2 (en) |
EP (1) | EP2491028B1 (en) |
JP (1) | JP5542946B2 (en) |
KR (1) | KR20120087923A (en) |
CN (1) | CN102666526A (en) |
AP (1) | AP2012006204A0 (en) |
AU (1) | AU2010308277A1 (en) |
BR (1) | BR112012009331A2 (en) |
CA (1) | CA2778060A1 (en) |
CL (1) | CL2012000967A1 (en) |
CO (1) | CO6531488A2 (en) |
DK (1) | DK2491028T3 (en) |
EA (1) | EA021015B1 (en) |
EC (1) | ECSP12011904A (en) |
ES (1) | ES2444780T3 (en) |
GE (1) | GEP20146103B (en) |
HR (1) | HRP20140213T1 (en) |
IL (1) | IL218823A0 (en) |
IN (1) | IN2012DN03449A (en) |
MA (1) | MA33675B1 (en) |
MX (1) | MX2012004644A (en) |
NZ (1) | NZ599132A (en) |
PE (1) | PE20121433A1 (en) |
PL (1) | PL2491028T3 (en) |
PT (1) | PT2491028E (en) |
RS (1) | RS53130B (en) |
SI (1) | SI2491028T1 (en) |
TN (1) | TN2012000180A1 (en) |
WO (1) | WO2011049917A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5216912B2 (en) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Indazole compounds as CCR1 receptor antagonists |
JP5411927B2 (en) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrazole compounds as CCR1 antagonists |
NZ591115A (en) | 2008-09-26 | 2012-10-26 | Boehringer Ingelheim Int | Azaindazole compounds as ccr1 receptor antagonists |
RS53130B (en) | 2009-10-21 | 2014-06-30 | Boehringer Ingelheim International Gmbh | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
WO2011056440A1 (en) * | 2009-10-27 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as ccr1 receptor antagonists |
EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
CN107266454B (en) | 2014-04-14 | 2019-08-09 | 勃林格殷格翰国际有限公司 | Compound as ROR gamma modulators |
CN112707831A (en) * | 2021-02-05 | 2021-04-27 | 阿里生物新材料(常州)有限公司 | Synthetic method of 3- (1-aminocyclopropyl) methyl benzoate |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1338625C (en) | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
ES2188584T3 (en) | 1991-03-28 | 2003-07-01 | Eisai Co Ltd | AMINA HETEROCICLICAL DERIVATIVES. |
US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
US5616537A (en) | 1992-07-03 | 1997-04-01 | Kumiai Chemical Industry Co., Ltd. | Condensed heterocyclic derivatives and herbicides |
WO1995000509A1 (en) | 1993-06-25 | 1995-01-05 | Kumiai Chemical Industry Co., Ltd. | Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof |
CA2207201A1 (en) | 1994-12-06 | 1996-06-13 | Caroline Henry | Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists |
GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
EP0939757A1 (en) | 1995-12-22 | 1999-09-08 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
JPH101478A (en) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | Indazolesulfonylurea derivative and herbicide |
GB9615449D0 (en) | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
YU25400A (en) | 1997-11-04 | 2003-07-07 | Pfizer Products Inc. | Therapeutically active compounds based on indazole |
US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
AU5413600A (en) | 1999-06-14 | 2001-01-02 | Eli Lilly And Company | Compounds |
JP2003502314A (en) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | Compound |
AU5895500A (en) | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
AU2000229243A1 (en) | 2000-03-02 | 2001-09-12 | Ndc Infrared Engineering Limited | Electromagnetic detection apparatus |
GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
GB0030305D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
GB0030306D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
GB0030304D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
US7058826B2 (en) | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
ATE455104T1 (en) | 2001-11-01 | 2010-01-15 | Icagen Inc | PYRAZOLAMIDE FOR USE IN THE TREATMENT OF PAIN |
WO2008011131A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
CA2478232C (en) | 2002-04-11 | 2011-06-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic amide derivatives as cytokine inhibitors |
WO2003101968A1 (en) | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
DK1531822T3 (en) | 2002-06-12 | 2009-12-07 | Chemocentryx Inc | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists in the treatment of inflammation and immune disorders |
WO2004014905A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
SE0203825D0 (en) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
EP1664052B1 (en) | 2003-08-15 | 2009-02-18 | AstraZeneca AB | Fused heterocycles as inhibitors of glutamate racemase (muri) |
CA2598531A1 (en) | 2005-02-24 | 2006-08-31 | Merck & Co., Inc. | Benzazole potentiators of metabotropic glutamate receptors |
GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
CA2609053C (en) | 2005-05-17 | 2017-04-25 | Sarcode Corporation | Compositions and methods for treatment of eye disorders |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
JP5275794B2 (en) | 2005-06-22 | 2013-08-28 | ケモセントリックス,インコーポレイティド | Azaindazole compounds and methods of use |
BRPI0615048A2 (en) | 2005-09-01 | 2010-03-30 | Lilly Co Eli | compound, pharmaceutical composition, and use of a compound |
US20080262040A1 (en) | 2005-10-25 | 2008-10-23 | Smithkline Beecham Corporation | Chemical Compounds |
AU2008206045A1 (en) | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
KR20100039862A (en) | 2007-06-26 | 2010-04-16 | 아스트라제네카 아베 | 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors |
US20110028507A1 (en) | 2007-08-10 | 2011-02-03 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
NZ585640A (en) | 2007-11-29 | 2011-03-31 | Boehringer Ingelhelheim Internat Gmbh | Derivatives of 6,7-dihydro-5h-imidazo[1,2-alpha]imidazole-3- carboxylic acid amides |
JP5216912B2 (en) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Indazole compounds as CCR1 receptor antagonists |
JP5411927B2 (en) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrazole compounds as CCR1 antagonists |
NZ591115A (en) | 2008-09-26 | 2012-10-26 | Boehringer Ingelheim Int | Azaindazole compounds as ccr1 receptor antagonists |
RS53130B (en) | 2009-10-21 | 2014-06-30 | Boehringer Ingelheim International Gmbh | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
WO2011056440A1 (en) | 2009-10-27 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as ccr1 receptor antagonists |
CN102596908A (en) | 2009-12-08 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
-
2010
- 2010-10-19 RS RS20140024A patent/RS53130B/en unknown
- 2010-10-19 WO PCT/US2010/053142 patent/WO2011049917A1/en active Application Filing
- 2010-10-19 JP JP2012535292A patent/JP5542946B2/en active Active
- 2010-10-19 SI SI201030538T patent/SI2491028T1/en unknown
- 2010-10-19 GE GEAP201012715A patent/GEP20146103B/en unknown
- 2010-10-19 EP EP10768356.7A patent/EP2491028B1/en active Active
- 2010-10-19 CA CA2778060A patent/CA2778060A1/en not_active Abandoned
- 2010-10-19 IN IN3449DEN2012 patent/IN2012DN03449A/en unknown
- 2010-10-19 KR KR1020127010143A patent/KR20120087923A/en not_active Application Discontinuation
- 2010-10-19 US US13/499,939 patent/US9056858B2/en active Active
- 2010-10-19 AU AU2010308277A patent/AU2010308277A1/en not_active Abandoned
- 2010-10-19 EA EA201200602A patent/EA021015B1/en not_active IP Right Cessation
- 2010-10-19 NZ NZ599132A patent/NZ599132A/en not_active IP Right Cessation
- 2010-10-19 BR BR112012009331A patent/BR112012009331A2/en not_active IP Right Cessation
- 2010-10-19 MX MX2012004644A patent/MX2012004644A/en active IP Right Grant
- 2010-10-19 CN CN2010800578454A patent/CN102666526A/en active Pending
- 2010-10-19 ES ES10768356.7T patent/ES2444780T3/en active Active
- 2010-10-19 DK DK10768356.7T patent/DK2491028T3/en active
- 2010-10-19 AP AP2012006204A patent/AP2012006204A0/en unknown
- 2010-10-19 PT PT107683567T patent/PT2491028E/en unknown
- 2010-10-19 PL PL10768356T patent/PL2491028T3/en unknown
- 2010-10-19 PE PE2012000493A patent/PE20121433A1/en not_active Application Discontinuation
-
2012
- 2012-03-25 IL IL218823A patent/IL218823A0/en unknown
- 2012-04-16 CL CL2012000967A patent/CL2012000967A1/en unknown
- 2012-04-16 MA MA34779A patent/MA33675B1/en unknown
- 2012-04-19 TN TNP2012000180A patent/TN2012000180A1/en unknown
- 2012-04-26 CO CO12068976A patent/CO6531488A2/en active IP Right Grant
- 2012-05-16 EC ECSP12011904 patent/ECSP12011904A/en unknown
-
2014
- 2014-03-10 HR HRP20140213AT patent/HRP20140213T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TN2012000180A1 (en) | 2013-12-12 |
RS53130B (en) | 2014-06-30 |
US9056858B2 (en) | 2015-06-16 |
CO6531488A2 (en) | 2012-09-28 |
KR20120087923A (en) | 2012-08-07 |
BR112012009331A2 (en) | 2019-09-24 |
JP2013508376A (en) | 2013-03-07 |
GEP20146103B (en) | 2014-05-27 |
WO2011049917A1 (en) | 2011-04-28 |
ECSP12011904A (en) | 2012-10-30 |
ES2444780T3 (en) | 2014-02-26 |
CL2012000967A1 (en) | 2012-09-14 |
CA2778060A1 (en) | 2011-04-28 |
EP2491028A1 (en) | 2012-08-29 |
EA021015B1 (en) | 2015-03-31 |
SI2491028T1 (en) | 2014-03-31 |
DK2491028T3 (en) | 2014-01-13 |
US20120270870A1 (en) | 2012-10-25 |
AU2010308277A1 (en) | 2012-04-26 |
MA33675B1 (en) | 2012-10-01 |
MX2012004644A (en) | 2012-05-08 |
JP5542946B2 (en) | 2014-07-09 |
AP2012006204A0 (en) | 2012-04-30 |
IL218823A0 (en) | 2012-06-28 |
HRP20140213T1 (en) | 2014-04-11 |
EP2491028B1 (en) | 2013-12-11 |
PE20121433A1 (en) | 2012-11-10 |
NZ599132A (en) | 2014-05-30 |
PT2491028E (en) | 2014-02-04 |
EA201200602A1 (en) | 2012-12-28 |
CN102666526A (en) | 2012-09-12 |
PL2491028T3 (en) | 2014-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN03449A (en) | ||
MX2010004028A (en) | 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one. | |
NI201100011A (en) | PYRIDINE DERIVATIVES - PYRIDINONES, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS. | |
DE602005014086D1 (en) | PYRIMIDINE DERIVATIVES AS OREXINE RECEPTOR ANTAGONISTS | |
EA200700365A1 (en) | INDOL-2-CARBOXAMIDINE DERIVATIVES AS ANTAGONISTS OF NMDA RECEPTOR | |
UA111640C2 (en) | DERIVATIVES [1,2,3] TRIAZOLO [4,5-d] PYRIMIDINE AS A cannabinoid receptor agonist 2 | |
CU20100115A7 (en) | USEFUL INTERMEDIATES FOR THE PREPARATION OF CARBOXAMIDE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC RECEIVER | |
PA8774201A1 (en) | RECEIVER ANTAGONIST | |
EA201290355A1 (en) | SPYROPYPERIDINE CONNECTIONS AS ANTAGONISTS OF ORL-1 RECEPTOR | |
EA201171062A1 (en) | ALKILAMIDE COMPOUNDS AND THEIR APPLICATION | |
MX2013005833A (en) | Novel fused pyridine compounds as casein kinase inhibitors. | |
MX2013001234A (en) | Deuterated tandospirone derivatives as 5-ht1a receptor agonists. | |
UY32517A (en) | DERIVATIVES OF NICOTINAMIDE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
UY32553A (en) | NEW DERIVATIVES OF PIRROLIDINADIONA ESPIROHETEROCÍCLICOS 3-REPLACED | |
MY152281A (en) | 4-pyrimidinesulfamide derivative | |
CR11157A (en) | DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
MA32957B1 (en) | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | |
UY30534A1 (en) | DERIVATIVES OF 5,6-BISARIL-2-PIRIDIN-CARBOXAMIDE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS | |
UA105767C2 (en) | Amorphous prothioconazole, microbicidal composition based thereon, process for the preparation thereof | |
RS51858B (en) | 4-[(3-fluorophenoxy)fhenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions | |
EA201170585A1 (en) | IZOHINOLINON DERIVATIVES AS ANTAGONISTS NK3 | |
EA201270421A1 (en) | 1,2-DIHYDRO-2-OXOHINOLINE COMPOUNDS AS LIGANDS OF 5-NT RECEPTOR | |
MA32479B1 (en) | Compounds new active as muscarinic receptor antagonists | |
EA201001870A1 (en) | NEW CRYSTAL SHAPES OF SODIUM CRUST TUNE | |
NI201200104A (en) | NEW DERIVATIVES OF (HETEROCYCLO - CONDENSED PIPERIDINE) - (PIPERAZINIL) - 1 - ALCANONE OR OF (HETEROCICLO - CONDENSED PYRROLIDINE) - (PIPERAZINIL) - 1 - ALCANONE AND ITS USE AS P75 INHIBITORS |